The headline reads as positive (10% confidence from the FinBERT financial-language model), so the stock went through the full analysis. Despite the positive headline, the broader picture leans negative: good news does not always mean a good trade.
Stocks › ALHC
Alignment Healthcare, Inc. (ALHC) stock analysis
WEAK SELL 23% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Alignment Healthcare, Inc. (ALHC) WEAK SELL with 23% confidence at a price of $8.06. That means the signals lean negative, but they are mixed, so conviction is low.
Analysed price$8.06
Technical picture
The 14-day RSI is 61, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 1.7x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $25.12 and the swing low is $13.05; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 0.9% and revenue growth of +31.6%.
In its latest quarter it earned $0.25 per share, which beat the $0.20 analysts expected, with revenue +31.6% year over year.
Wall Street's average rating is 1.9 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $12.31.
Trade plan from the model
The model's short / bearish plan uses an entry near $8.06, a target of $7.38 (-8.4%) and a stop-loss at $8.85 (+9.8%).
That is a reward-to-risk ratio of about 0.9 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 9, 2026 whatever the price does.
Entry$8.06
Target$7.38
Stop-loss$8.85
Reassess byNov 9, 2026
Research notes
ALHC’s bull case remains strong membership and revenue growth: Q3 2026 membership increased 31% year over year, revenue rose 37% to $1.36 billion, and six of seven eligible plans retained ratings of at least four stars. The bear case has intensified as medical costs lifted the medical loss ratio to 89.5%, profitability weakened, and management cut full-year adjusted EBITDA guidance to at least $100 million; its largest California HMO contract also fell to 3.5 stars, threatening quality-bonus revenue. The major recent catalyst was the Q3 report, which beat revenue estimates but triggered a sharp after-hours share decline because of lower guidance and cost pressure. This latest information and price action support the prior neutral view: operating growth is encouraging, but the 2.9% decline since the $8.06 assessment reflects worsening near-term earnings risks.
The model's one-paragraph read
Leans SELL / avoid — composite score -0.23 (WEAK SELL). Technicals: RSI 61.22, MACD bullish, price below SMA50. Fundamentals: margin 0.9%, revenue growth 31.6%. Financial results: YoY revenue +31.6%, last EPS surprise +25.0%. Smart Money Concepts: BOS bearish (trend continuation), price retesting a bullish order block, price retesting a bearish order block, sitting inside an unfilled bullish fair value gap. FinGPT news read: positive. Memory: 1 prior look(s); 0% of directional calls matched later price. Internet research: ALHC’s **bull case** remains strong membership and revenue growth: Q3 2026 membership increased 31% year over year, revenue rose 37% to $1.36 billion, and six of seven eligible plans retained ratings of at least four stars. The **bear case** has intensified as medical costs lifted the medical loss ratio to 89.5%, profitability weakened, and management cut full-year adjusted EBITDA guidance to at least $100 million; its largest California HMO contract also fell to 3.5 stars, threatening quality-bonus revenue. The major recent catalyst was the Q3 report, which beat revenue estimates but triggered a sharp after-hours share decline because of lower guidance and cost pressure. This latest information and price action support the prior **neutral** view: operating growth is encouraging, but the 2.9% decline since the $8.06 assessment reflects worsening near-term earnings risks. Suggested levels: entry $8.06, target $7.38, stop-loss $8.85, exit by 2026-11-09 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for ALHC
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK SELL | 23% | $8.06 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on ALHC
Oct 30, 2026 · Alignment Healthcare Matches EPS Forecast, But A Medical-Cost Surge Forces A Steep Profit Reset Despite Accelerating Growth
Oct 13, 2026 · ALHC: Alignment Healthcare Investors Should Contact Block & Leviton to Possibly Recover Losses
The headline reads as positive (75% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
- Oct 29, 2026: Alignment Healthcare, Inc. Reports Third Quarter 2026 Revenue of $1.36 Billion and Lowers Certain Full-Year Guidance (Nasdaq)
- Oct 29, 2026: Alignment Healthcare Matches EPS Forecast, But A Medical-Cost Surge Forces A Steep Profit Reset Despite Accelerating Growth (Earnings Whispers)
- Oct 29, 2026: Alignment Healthcare: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook (GlobeNewswire)
Frequently asked questions
Is ALHC a buy right now?
As of Oct 30, 2026, our automated model rates Alignment Healthcare, Inc. (ALHC) WEAK SELL with 23% confidence: the signals lean negative, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ALHC?
The model's most recent plan targets $7.38 with a stop-loss at $8.85, from an entry near $8.06.
What does a WEAK SELL rating mean?
A WEAK SELL rating means the signals lean negative, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.